Krebs

In einem Gastbeitrag in Le Monde kritisiert Philippe Bergerot, Präsident der Ligue contre le cancer, den Fokus des Staates auf Heilbehandlung und plädiert für lokale Präventionsmaßnahmen vor den Kommunalwahlen und dem Weltkrebstag am 4. Februar.

2. Februar 2026 Von KI berichtet

A randomized trial shows that administering cancer immunotherapy before 3pm can nearly double survival time for patients with non-small cell lung cancer. Researchers found significant benefits from aligning treatment with circadian rhythms during the initial cycles. This marks the strongest evidence yet for chronotherapy in oncology.

Scientists at Moffitt Cancer Center report developing a computational method, ALFA-K, that uses longitudinal single-cell measurements to infer how gains and losses of whole chromosomes can shape a tumor’s evolutionary path. The work, published in Nature Communications, argues that these large-scale chromosome changes follow measurable patterns influenced by cellular context and treatment-related stress rather than unfolding as pure randomness.

24. Januar 2026 Von KI berichtet

A new study reveals that chemotherapy's damage to the gut lining unexpectedly rewires the microbiota, producing a compound that strengthens immune defenses against cancer spread. This process reduces immunosuppressive cells and enhances resistance to metastasis, particularly in the liver. Patient data links higher levels of this compound to improved survival in colorectal cancer cases.

Researchers have discovered that a byproduct of vitamin A, all-trans retinoic acid, weakens the immune system's fight against cancer and reduces the effectiveness of certain vaccines. In preclinical studies, a new drug called KyA33 blocks this pathway, enhancing immune responses and slowing tumor growth. The findings, from two studies, explain a long-standing paradox about vitamin A's role in cancer.

15. Januar 2026 Von KI berichtet

Scientists at Northwestern Medicine have developed an antibody that counters pancreatic cancer's sugar-based disguise, enabling the immune system to attack tumors more effectively. In mouse studies, the therapy slowed tumor growth by restoring immune activity. The team is preparing the antibody for human trials.